HRP20000277A2 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
HRP20000277A2
HRP20000277A2 HR20000277A HRP20000277A HRP20000277A2 HR P20000277 A2 HRP20000277 A2 HR P20000277A2 HR 20000277 A HR20000277 A HR 20000277A HR P20000277 A HRP20000277 A HR P20000277A HR P20000277 A2 HRP20000277 A2 HR P20000277A2
Authority
HR
Croatia
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
HR20000277A
Other languages
English (en)
Inventor
Colin David Eldred
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HRP20000277A2 publication Critical patent/HRP20000277A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
HR20000277A 1997-11-08 2000-05-08 Chemical compounds HRP20000277A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723590.7A GB9723590D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007023 WO1999024451A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
HRP20000277A2 true HRP20000277A2 (en) 2000-10-31

Family

ID=10821761

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000277A HRP20000277A2 (en) 1997-11-08 2000-05-08 Chemical compounds

Country Status (27)

Country Link
US (2) US6544960B1 (xx)
EP (1) EP1030856B1 (xx)
JP (1) JP2001522859A (xx)
KR (1) KR20010031878A (xx)
CN (1) CN1217952C (xx)
AP (1) AP2000001804A0 (xx)
AT (1) ATE273989T1 (xx)
AU (1) AU763414B2 (xx)
BR (1) BR9813989A (xx)
CA (1) CA2309202C (xx)
DE (1) DE69825779T2 (xx)
EA (1) EA003087B1 (xx)
EE (1) EE04499B1 (xx)
ES (1) ES2222619T3 (xx)
GB (1) GB9723590D0 (xx)
HR (1) HRP20000277A2 (xx)
HU (1) HUP0004102A3 (xx)
ID (1) ID24758A (xx)
IL (2) IL135966A0 (xx)
IS (1) IS5479A (xx)
NO (1) NO20002359L (xx)
NZ (1) NZ504336A (xx)
PL (1) PL340873A1 (xx)
SK (1) SK6702000A3 (xx)
TR (1) TR200001937T2 (xx)
WO (1) WO1999024451A2 (xx)
YU (1) YU26800A (xx)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
GB9930085D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
GB0221694D0 (en) * 2002-09-18 2002-10-30 Glaxo Group Ltd Compounds
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2515068A1 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
ES2670413T3 (es) 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
WO2007064795A2 (en) * 2005-11-30 2007-06-07 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0714629A2 (pt) 2006-08-21 2013-05-07 Genentech Inc composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
AU2009204370B2 (en) 2008-01-04 2014-12-04 Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services Ketone bodies and ketone body esters as blood lipid lowering agents
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
CN101602786B (zh) * 2008-06-10 2014-04-30 中国医学科学院药物研究所 N6-取代腺苷衍生物、其制法以及药物组合物与用途
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
CN104382924B (zh) * 2009-12-10 2017-12-22 中国医学科学院药物研究所 N6‑取代腺苷衍生物和n6‑取代腺嘌呤衍生物及其用途
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
ES2752030T3 (es) 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
SG11201507685UA (en) 2013-03-14 2015-10-29 Isis Innovation Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868160A (en) * 1985-11-06 1989-09-19 Warner-Lambert Company Method of treating psychosis using N6 -substituted -5'-oxidized adenosine analogs
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
JPH0723394B2 (ja) * 1986-11-27 1995-03-15 日本臓器製薬株式会社 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DK0550631T3 (da) * 1990-09-25 1997-01-20 Rhone Poulenc Rorer Int Forbindelser med blodtrykssænkende virkning og virkning mod iskæmi
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
DK62592D0 (xx) * 1992-05-14 1992-05-14 Novo Nordisk As
EP0601322A3 (en) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JPH07118156A (ja) * 1993-10-26 1995-05-09 Nippon Zoki Pharmaceut Co Ltd アデノシンデアミナーゼ阻害剤
JPH08269083A (ja) * 1995-04-03 1996-10-15 Banyu Pharmaceut Co Ltd Ｎ６−置換アデノシン誘導体
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE273989T1 (de) 2004-09-15
AU763414B2 (en) 2003-07-24
IL135966A (en) 2006-06-11
JP2001522859A (ja) 2001-11-20
EP1030856B1 (en) 2004-08-18
CA2309202A1 (en) 1999-05-20
BR9813989A (pt) 2000-09-26
ID24758A (id) 2000-08-03
ES2222619T3 (es) 2005-02-01
US6740644B2 (en) 2004-05-25
NZ504336A (en) 2002-11-26
HUP0004102A2 (hu) 2001-04-28
EA003087B1 (ru) 2002-12-26
AU1666599A (en) 1999-05-31
AP2000001804A0 (en) 2000-06-30
EE04499B1 (et) 2005-06-15
IL135966A0 (en) 2001-05-20
CN1285844A (zh) 2001-02-28
CA2309202C (en) 2008-06-17
DE69825779T2 (de) 2005-08-25
WO1999024451A2 (en) 1999-05-20
SK6702000A3 (en) 2001-01-18
WO1999024451A3 (en) 1999-08-19
GB9723590D0 (en) 1998-01-07
TR200001937T2 (tr) 2000-11-21
EE200000283A (et) 2001-08-15
YU26800A (sh) 2002-12-10
DE69825779D1 (de) 2004-09-23
PL340873A1 (en) 2001-03-12
US6544960B1 (en) 2003-04-08
EP1030856A2 (en) 2000-08-30
EA200000398A1 (ru) 2000-12-25
NO20002359L (no) 2000-07-05
HUP0004102A3 (en) 2002-09-30
IS5479A (is) 2000-05-03
CN1217952C (zh) 2005-09-07
KR20010031878A (ko) 2001-04-16
US20030158146A1 (en) 2003-08-21
NO20002359D0 (no) 2000-05-05

Similar Documents

Publication Publication Date Title
GB9705361D0 (en) Chemical compounds
HRP20000277A2 (en) Chemical compounds
GB9704208D0 (en) Chemical compounds
GB9717804D0 (en) Chemical compounds
GB9708530D0 (en) Chemical compounds
GB9703201D0 (en) Chemical compounds
GB9708119D0 (en) Chemical compounds
GB9705212D0 (en) Chemical compounds
GB9706707D0 (en) Chemical compounds
GB9711994D0 (en) Chemical compounds
GB9715768D0 (en) Chemical compounds
GB9711143D0 (en) Chemical compounds
GB9713410D0 (en) Chemical compounds
GB9705830D0 (en) Chemical compounds
GB9707452D0 (en) Chemical compounds
GB9708115D0 (en) Chemical compounds
GB9704809D0 (en) Chemical compounds
GB9708153D0 (en) Chemical compounds
GB9703136D0 (en) Chemical compounds
GB9703027D0 (en) Chemical compounds
GB9709831D0 (en) Chemical compounds
GB9702998D0 (en) Chemical compounds
GB9703200D0 (en) Chemical compounds
GB9711708D0 (en) Chemical compounds
GB9704224D0 (en) Chemical compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20041013

Year of fee payment: 7

ODBC Application rejected